Skip to main content
. 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885

Table 5.

Other KRAS-targeting strategies.

Compound Mechanism of Action Indication
KRAS peptide vaccine Vaccine
  • -

    In combination with Nivolumab and Ipilimumab for stage III/IV unresectable NSCLC (NCT05254184)
Targovax TG-01/Stimulon QS-21 Vaccine
  • -

    In combination with Daratumumab and Nivolumab in advanced NSCLC (NCT06015724)
KRAS TCR-Transduced PBL and GRT-C903/GRT-R904 KRAS TCR-transduced PBL in combination
with KRAS G12D
and G12V vaccine
FH-A11KRASG12V-TCR Autologous transgenic T cells expressing high-affinity KRASG12V mutation-specific T cell receptors
AFNT-211 Autologous CD8+ and CD4+ engineered T
cell receptor T Cell
  • -

    In advanced or metastatic solid tumors with KRAS G12V mutation (NCT06105021)
NT-112 KRAS G12D autologous
T cell therapy
  • -

    Unresectable, advanced, and/or metastatic NSCLC (NCT06218914)